Vinci Pharmaceuticals Secures $8 Million in Series A Funding
Vinci Pharmaceuticals, based in Avon-by-the-sea, New Jersey, has announced the successful completion of its Series A funding round, raising $8 million. The funding was led by Dynagrow Capital with participation from MintPharma Capital. Vinci Pharmaceuticals is working on innovative solutions for retinal disease treatment through its proprietary needle-free drug delivery platform, EPIPLANT™.
Leadership and Vision
Philip Gioia, the CEO of Vinci Pharmaceuticals, leads the company in its mission to transform the treatment landscape for retinal diseases. With the new funding, Vinci aims to accelerate the development and deployment of EPIPLANT™.
Use of Funds
The $8 million raised in this Series A round will primarily be used to advance the EPIPLANT™ platform. This includes further research and development, scaling manufacturing capabilities, and potentially expanding the company's market reach.
Investors
The Series A round was spearheaded by Dynagrow Capital, a firm known for investing in disruptive healthcare technologies. MintPharma Capital also participated in this funding round, supporting Vinci Pharmaceuticals' innovative approach to drug delivery.
Conclusion
This funding round marks a significant step for Vinci Pharmaceuticals as it continues to innovate in the field of retinal disease treatment. By leveraging the new capital, the company aims to enhance its EPIPLANT™ platform, bringing needle-free solutions to patients worldwide.